JP5394404B2 - キナーゼ阻害剤として有用な置換イミダゾピリダジン類 - Google Patents

キナーゼ阻害剤として有用な置換イミダゾピリダジン類 Download PDF

Info

Publication number
JP5394404B2
JP5394404B2 JP2010546068A JP2010546068A JP5394404B2 JP 5394404 B2 JP5394404 B2 JP 5394404B2 JP 2010546068 A JP2010546068 A JP 2010546068A JP 2010546068 A JP2010546068 A JP 2010546068A JP 5394404 B2 JP5394404 B2 JP 5394404B2
Authority
JP
Japan
Prior art keywords
substituted
alkyl
heterocyclo
heteroaryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010546068A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011511095A5 (OSRAM
JP2011511095A (ja
Inventor
ブライアン・イー・フィンク
リビン・チェン
ピン・チェン
ダームパル・エス・ドッド
アシュビニクマー・ブイ・ガバイ
ソン−ホン・キム
ウェイン・バッカロ
リタイ・エイチ・チャン
ユフェン・チャオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2011511095A publication Critical patent/JP2011511095A/ja
Publication of JP2011511095A5 publication Critical patent/JP2011511095A5/ja
Application granted granted Critical
Publication of JP5394404B2 publication Critical patent/JP5394404B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2010546068A 2008-02-06 2009-02-06 キナーゼ阻害剤として有用な置換イミダゾピリダジン類 Expired - Fee Related JP5394404B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2665108P 2008-02-06 2008-02-06
US61/026,651 2008-02-06
PCT/US2009/033455 WO2009100375A1 (en) 2008-02-06 2009-02-06 Substituted imidazopyridazines useful as kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2011511095A JP2011511095A (ja) 2011-04-07
JP2011511095A5 JP2011511095A5 (OSRAM) 2011-09-29
JP5394404B2 true JP5394404B2 (ja) 2014-01-22

Family

ID=40566064

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010546068A Expired - Fee Related JP5394404B2 (ja) 2008-02-06 2009-02-06 キナーゼ阻害剤として有用な置換イミダゾピリダジン類

Country Status (5)

Country Link
US (1) US8389527B2 (OSRAM)
EP (1) EP2240488B1 (OSRAM)
JP (1) JP5394404B2 (OSRAM)
CN (1) CN101981033B (OSRAM)
WO (1) WO2009100375A1 (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
EP2210891A1 (en) * 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
JP2013501003A (ja) * 2009-07-31 2013-01-10 バイオクライスト ファーマシューティカルズ， インコーポレイテッド ヤヌスキナーゼ阻害剤としてのピロロ［１，２−ｂ］ピリダジン誘導体
US8575177B2 (en) * 2009-12-04 2013-11-05 Senhwa Biosciences, Inc. Pyrazolopyrimidines and related heterocycles as CK2 inhibitors
JPWO2011078221A1 (ja) 2009-12-24 2013-05-09 味の素株式会社 イミダゾピリダジン化合物
EP2563792B1 (en) * 2010-04-28 2014-08-27 Bristol-Myers Squibb Company Imidazopyridazinyl compounds and their uses for cancer
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
DE102011075398A1 (de) * 2011-05-06 2012-11-08 Bayer Pharma Aktiengesellschaft Substituierte Imidazopyridazine und ihre Verwendung
CN104394869A (zh) * 2011-10-20 2015-03-04 葛兰素史密斯克莱有限责任公司 用作沉默调节蛋白调节剂的取代的双环氮杂杂环化合物和类似物
WO2013142817A2 (en) 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
JP6283688B2 (ja) * 2012-12-21 2018-02-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン
TW201437211A (zh) * 2013-03-01 2014-10-01 Bayer Pharma AG 經取代咪唑并嗒□
US20160199372A1 (en) * 2013-08-20 2016-07-14 Bristol-Myers Squibb Company Imidazopyridazine kinase inhibitors useful to treating a disease or disorder mediated by aak1, such as alzheimer's disease, bipolar disorder, pain, schizophrenia
EP3054955B1 (en) 2013-10-11 2018-05-30 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
ES2702126T3 (es) * 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
ES2770693T3 (es) * 2014-06-19 2020-07-02 Bristol Myers Squibb Co Derivados de imidazopiridazina como inhibidores de caseína quinasa 1 delta/épsilon
CA2966581A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
DK3215511T3 (da) 2014-11-06 2024-05-13 Bial R&D Invest S A Substituerede pyrazolo(1,5-a)pyrimidiner og deres anvendelse i behandlingen af medicinske lidelser
ES2958391T3 (es) 2014-11-06 2024-02-08 Bial R&D Invest S A Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos
EP3268367B8 (en) * 2015-03-12 2022-11-16 Merck Sharp & Dohme LLC Carboxamide inhibitors of irak4 activity
EP3377496B1 (en) 2015-11-18 2020-09-16 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
JP7046827B2 (ja) 2016-04-06 2022-04-04 リソソーマル・セラピューティクス・インコーポレイテッド イミダゾ［１，５－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用
WO2017176960A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
WO2017176962A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics, Inc. Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
BR112018072552A8 (pt) * 2016-05-05 2023-03-14 Lysosomal Therapeutics Inc Compostos de imidazo [1,2-b]piridazinas e imidazo [1,5-b] piridazinas substituídas, composição farmacêutica que os compreende e seu uso no tratamento de distúrbios médicos
US11345698B2 (en) 2016-05-05 2022-05-31 Bial—R&D Investments, S.A. Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders
EP3498693B1 (en) * 2016-08-10 2024-10-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
MA46453A (fr) * 2016-10-07 2019-08-14 Bristol Myers Squibb Co Composés imidazopyridazine utiles en tant que modulateurs de réponses il-12, il-23 et/ou ifn alpha
ES2849974T3 (es) * 2016-11-17 2021-08-24 Bristol Myers Squibb Co Moduladores de imidazopiridazina de IL-12, IL-23 y/o IFNalfa
PL3568396T3 (pl) * 2017-01-11 2021-05-31 Leo Pharma A/S Nowe pochodne aminoimidazopirydyny jako inhibitory kinaz janusowych i ich zastosowanie farmaceutyczne
CA3126034A1 (en) * 2019-01-23 2020-07-30 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
EP3935058B1 (en) * 2019-03-05 2024-08-21 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
WO2022156657A1 (en) * 2021-01-19 2022-07-28 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Imidazolopyridazine or pyrazolopyrimidine compounds and compositions

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH635587A5 (fr) * 1978-01-09 1983-04-15 Aron Sa Derives amines de pyrazolo (1,5-a) s.triazine, therapeutiquement actifs et leurs procedes de preparation.
US4464372A (en) * 1982-08-16 1984-08-07 Schering Corporation Imidazo[1,2-b]pyridazines
DE3446812A1 (de) 1984-12-21 1986-06-26 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazoderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
DE3446778A1 (de) * 1984-12-21 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazoderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
US4838925A (en) * 1986-04-25 1989-06-13 E. I. Du Pont De Nemours And Company Heterocyclic acyl sulfonamides
CA1273336A (en) 1986-04-25 1990-08-28 Chi-Ping Tseng Herbicidal heterocyclic carbonyl sulfonamides
FR2619818B1 (fr) 1987-09-01 1990-01-12 Sanofi Sa Imidazo (1,2-b) pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant
CA2057089A1 (en) 1990-12-07 1992-06-08 Eric E. Allen Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin ii antagonists
JPH07101958A (ja) 1992-10-16 1995-04-18 Takeda Chem Ind Ltd セフェム化合物、その製造法および抗菌組成物
JPH07133280A (ja) 1993-11-09 1995-05-23 Takeda Chem Ind Ltd セフェム化合物、その製造法および抗菌組成物
DE19912636A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
CN1308327C (zh) 2000-04-27 2007-04-04 安斯泰来制药有限公司 咪唑并吡啶衍生物
CA2432417A1 (fr) * 2000-12-20 2002-06-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R .A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
FR2825278A1 (fr) 2001-05-30 2002-12-06 Sod Conseils Rech Applic Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
AU2003217712A1 (en) 2002-03-07 2003-09-22 Smithkline Beecham Corporation Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
MXPA05008955A (es) * 2003-02-28 2006-02-22 Teijin Pharma Ltd Derivados de pirazolo [1,5-a] pirimidina.
CL2004000817A1 (es) 2003-04-17 2005-04-15 Basf Ag Compuestos biciclos que contienen n; composicion que las contiene; utiles para combatir hongos fitopatogenos.
FR2856688B1 (fr) 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
EP1666468A4 (en) 2003-09-09 2007-03-21 Ono Pharmaceutical Co CRF ANTAGONISTS AND HETEROBICYCLIC COMPOUNDS
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
ATE390424T1 (de) 2004-08-02 2008-04-15 Sanol Arznei Schwarz Gmbh Carboxamide des indolizins und seiner aza- und diazaderivate
CA2576949A1 (en) 2004-08-13 2006-02-16 Teijin Pharma Limited Pyrazolo[1,5-a]pyrimidine derivatives
WO2006070943A1 (ja) 2004-12-28 2006-07-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
TW200716629A (en) 2005-03-17 2007-05-01 Teijin Pharma Ltd Pyrazolopyrimidine derivative or pharmaceutically acceptable salt thereof
KR20070120963A (ko) 2005-03-21 2007-12-26 일라이 릴리 앤드 캄파니 이미다조피리다진 화합물
CN101180299B (zh) 2005-03-23 2010-12-15 弗·哈夫曼-拉罗切有限公司 作为mglur2拮抗剂的乙炔基-吡唑并嘧啶衍生物
US7557103B2 (en) 2005-04-05 2009-07-07 Eli Lilly And Company Imidazopyridazine compounds
US20100216798A1 (en) 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
AR062207A1 (es) * 2006-08-04 2008-10-22 Takeda Pharmaceutical Derivados de imidazopiridazina inhibidores de quinasas utiles para prevenir y/o tratar el cancer.
EP2125819B1 (en) * 2007-03-21 2014-10-22 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
JP2011529073A (ja) 2008-07-24 2011-12-01 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ調節因子として有用な縮合ヘテロ環化合物
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈

Also Published As

Publication number Publication date
CN101981033A (zh) 2011-02-23
US8389527B2 (en) 2013-03-05
CN101981033B (zh) 2015-02-04
WO2009100375A1 (en) 2009-08-13
JP2011511095A (ja) 2011-04-07
US20100323994A1 (en) 2010-12-23
EP2240488A1 (en) 2010-10-20
EP2240488B1 (en) 2016-11-02

Similar Documents

Publication Publication Date Title
JP5394404B2 (ja) キナーゼ阻害剤として有用な置換イミダゾピリダジン類
KR101392678B1 (ko) 피롤로트리아진 키나제 억제제
US7531539B2 (en) Pyrrolotriazine kinase inhibitors
KR101784977B1 (ko) ＴＲＫ 키나아제 억제제로서의 치환된 피라졸로 〔1,5-ａ〕피리미딘 화합물
CN101594871B (zh) 吡咯并嘧啶化合物及其用途
CN103261167B (zh) 取代的6，6-稠合含氮杂环化合物及其用途
JP6035423B2 (ja) 新規な縮合ピリミジン化合物又はその塩
CN102245610B (zh) 吡咯并三嗪激酶抑制剂
JP5225288B2 (ja) キナーゼ阻害剤として有用なチアゾリル化合物
JP6267231B2 (ja) カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール
US9956220B2 (en) Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors
CN104837844B (zh) 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
JP2021525783A (ja) Ｅｒｋ阻害剤及びその使用
EP2552922A1 (en) Substituted pyrrolotriazines as protein kinase inhibitors
CN101883774A (zh) 噻吩并嘧啶和吡唑并嘧啶化合物及其用作mtor激酶和pi3激酶抑制剂的用途
IL297963A (en) Antagonists of the adenosine a2a receptor
KR20180021702A (ko) TBK/IKKε 억제제 화합물 및 이의 용도
JP2021504380A (ja) Ｐｄｅ１阻害剤としての置換フラノピリミジン化合物
BR112020019595A2 (pt) Composto, e, medicamento.
WO2016050201A1 (zh) 高选择性取代嘧啶类pi3k抑制剂
WO2024131265A1 (zh) 用于治疗PI3Kγ介导的疾病的化合物及其用途
EA048315B1 (ru) Ингибиторы fgfr и способы их применения
CN111217816A (zh) 一类flt3激酶抑制剂及其制备和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110810

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130625

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131008

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131016

R150 Certificate of patent or registration of utility model

Ref document number: 5394404

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees